To test our hypothesis, we collected tumor samples from HER2-positive breast cancer patients who had received neoadjuvant trastuzumab-containing regimens, and divided the patients into trastuzumab-sensitive and trastuzumab-resistant groups based on whether their Miller-Payne scores were greater than 2. This evidence concerns the gene ERBB2 and neoplasm.